Interleukin-17A (IL17A) Antibody
299€ (50 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Interleukin-17A (IL17A) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx402358
tested applications
ELISA
Description
Interleukin-17A (IL17A) Antibody is a Recombinant Human Monoclonal antibody for the detection of Human IL17A.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Interleukin-17A (IL17A) |
| Host | Human |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG4 (S228P) |
| Expression | Recombinant |
| Purification | Purified by affinity chromatography. |
| Size 1 | 50 µl |
| Size 2 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q16552 |
| Alias | IL17,CTLA8,IL-1,ILA17,CTLA-8,IL-17A |
| Background | Antibody anti-IL17A |
| Status | RUO |
Descripción
IL17A is a pro-inflammatory cytokine produced primarily by T-helper 17 (Th17) cells and other immune cells in response to infection and tissue damage IL17A plays a central role in innate and adaptive immunity by stimulating the production of chemokines, cytokines, and antimicrobial peptides that recruit neutrophils and enhance host defense against bacterial and fungal infections Dysregulated IL17A production is associated with autoimmune diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease, where it contributes to chronic inflammation and tissue damage IL17A also plays a role in cancer, where it can promote tumor growth and metastasis by inducing angiogenesis, immune suppression, and chronic inflammation IL17A-targeted therapies, including monoclonal antibodies such as secukinumab, have been developed to treat autoimmune and inflammatory conditions by neutralizing IL17A activity and reducing inflammation
Related Products
APC Anti-Mouse IL-17A Antibody(TC11-18H10.1)
Ver ProductoAPC Anti-Human IL-17A (BL168)
Ver Producto